NBE-002 in Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Triple Negative Breast Cancer
Related studies linked through entity extraction aliases.
Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE2
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Status
- RECRUITING
- Phase
- PHASE2
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
- Status
- RECRUITING
- Phase
- PHASE1
Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
- Status
- COMPLETED
- Phase
- PHASE2
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
- Status
- UNKNOWN
- Phase
- PHASE3
Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC
- Status
- COMPLETED
- Phase
- N/A
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
- Status
- TERMINATED
- Phase
- PHASE3
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers
- Status
- COMPLETED
- Phase
- PHASE2
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy
- Status
- UNKNOWN
- Phase
- PHASE2
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
- Status
- TERMINATED
- Phase
- PHASE1
Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women
- Status
- WITHDRAWN
- Phase
- N/A